Citations

Clear

62 citation(s) found for "Johnson, David".

CA19-9 and surgical margin status (SMS) associations with local-regional (LRF) and distant failure (DF) in patients (Pts) with pancreatic cancer: RTOG 9704 secondary analysis.
Regine, William F., Winter, Kathryn, Kessel, Ivan L., Chen, Yuhchyau , Fugazzi, James A., Donnelly, Eric D. , DiPetrillo, Thomas A., Gaur, Rakesh , Delouya, Guila , Haddock, Michael G. , Didolkar, Mukund S., Padula, Gilbert D. A. , Johnson, David B. , Hoffman, John P., Crane, Christopher H. , Narayan, Samir , Plastaras, John Peter , Suh, John H. , Meyer, Joshua E.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 3_suppl | Pages: 347-347

10.1200/jco.2015.33.3_suppl.347 Get It

347 Background: 9,704 was the first phase 3 pancreatic cancer trial to validate the prognostic value of postresection CA19-9 for overall survival (OS), with values > 90/180 associated with worse OS. All pts received adjuvant gemcitabine or 5-FU and chemo-radiotherapy (RT). This analysis evaluates patterns of disease failure. Methods: SMS was negative, positive, or unknown. CA19-9 was analyzed at cut points 90, 180 and continuously. LRF and DF were estimated by cumulative incidence and Gray’s test compared. Cox hazard models were used for multivariate analyses (MVA) and included treatment, tumor site, size and nodal status. To adjust for multiple comparisons a p-value < 0.01 is statistically significant and 0.01 to < 0.05 a trend. Results: 538 pts accrued, with 451 eligible and analyzable for SMS and 385 for CA19-9. For CA19-9, 132 (34%) were Lewis Antigen negative (no CA19-9 expression), 200 (52%) < 90 and 220 (57%) < 180. 188 (42%) had negative margins, 152 (34%) positive and 111 (25%) unknown (i.e., no margin comment in path report; shown to have outcomes similar to negative margin pts). Pts with CA19-9 ≥ 180 were more likely to have tumors ≥ 3 cm and pts with positive SMS more likely to have KPS 60 - 80, T3/T4, or N1 disease. On univariate analysis (UVA) CA19-9 cut at 90 was associated with significant increases in both LRF (trend) and DF; in the gemcitabine arm this was seen in DF, not in LRF; in the 5-FU arm it was seen in both. Results were similar at the 180 cut point and continuously. SMS on UVA was not associated with increase in LRF/DF; see Table. On MVA, CA19-9 > 90 was significantly associated with LRF and DF; positive SMS showed only a trend for DF. Conclusions: Postresection CA19-9 has significant association with both LRF and DF not seen with SMS. These findings support continued use of RT in trials and consideration of dose intensification among pts with elevated postresection CA19-9. Grants: NCI U10, CA21661, CA37422, CA180868, CA180822. Clinical trial information: 0000000. [Table: see text]
Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309)
Albain, Kathy S. , Turrisi, Andrew T., Smith, Colum J , Johnson, David H. , Green, M. R., Miller, R., Swann, Ruth , Rusch, Valerie W. , Shepherd, Frances Alice , Gandara, David R.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 7014-7014

10.1200/jco.2005.23.16_suppl.7014 Get It

Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study
Cotter, Thomas G. , Burger, Kelli N. , Devens, Mary E., Simonson, Julie A., Lowrie, Kari L., Heigh, Russell I., Johnson, David H. , Ahlquist, David A. , Mahoney, Douglas W. , Kisiel, John B. , Cotter, T G

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 20, 2016 | Volume: 26 | Issue: 4 | Pages: 614-621

10.1158/1055-9965.epi-16-0800 | PMID 27999144 Get It

Abstract Background: Studies of colorectal cancer screening by multitarget stool DNA (MT-sDNA) show false-positive (FP) rates of 7% to 13%. It is unclear whether FP patients are at increased long-term risk of adverse outcomes. Methods: We compared subsequent clinical events among patients with apparent FP MT-sDNA with those in patients reported as true negative (TN). This was a retrospective cohort study of participants in pre-FDA approval MT-sDNA studies having nonadvanced or negative baseline colonoscopy findings from a single referral center. Per-protocol and calibrated cutoffs defined FP and TN groups. From the time of stool collection, we measured differences between FP and TN groups in time to death, subsequent cancer diagnosis, and onset of alarm symptoms. Results: Of 1,050 eligible patients, only 6 were lost to follow-up. Median age was 65.6 years [interquartile range (IQR), 56.8–72.3]; 54% were female. Median follow-up time was 4 years (IQR, 3.5–5.3). Eight aerodigestive (lung and gastrointestinal tract) cancers occurred. FP status by calibrated, but not per-protocol, cutoffs was associated with subsequent aerodigestive cancer; however, cumulative incidence did not exceed SEER expectations from the general population. By any cutoff method, FP status was not associated with mortality or alarm symptoms. Conclusions: Although FP status was associated with long-term aerodigestive cancers, new cases were not temporally related and did not exceed incidence estimates from general population. Impact: These observations do not justify aggressive follow-up evaluation for patients with FP MT-sDNA at this time. Larger studies are needed to confirm these early findings. Cancer Epidemiol Biomarkers Prev; 26(4); 614–21. ©2016 AACR.
Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy
Lynn, Amanda M., Singh, Siddharth , Congly, Stephen E. , Khemani, Disha, Johnson, David H., Wiesner, Russell H., Kamath, Patrick S. , Andrews, James C. , Leise, Michael D.

Mayo Clinic

Liver Transplantation | March 12, 2016 | Volume: 22 | Issue: 6 | Pages: 723-731

10.1002/lt.24440 | PMID 26970243 Get It

Treatment options for refractory hepatic encephalopathy (HE) are limited. Patients who fail medical management may harbor large portosystemic shunts (PSSs) which are possible therapeutic targets. This study aims to describe patient selection, effectiveness, and safety of percutaneous PSS embolization in those with medically refractory HE. A retrospective evaluation of consecutive adult patients with medically refractory HE referred for PSS embolization at a tertiary center was performed (2003‐2015). Patient data collected included the type of HE, medications, Model for End‐Stage Liver Disease (MELD) score, shunt type, embolization approach, and materials used. Outcomes of interest were immediate (7 days), intermediate (1‐4 months), and longer‐term (6‐12 months) effectiveness and periprocedural safety. Effectiveness was determined based on changes in hospitalization frequency, HE medications, and symptoms. Twenty‐five patients with large PSS were evaluated for shunt embolization. Five were excluded due to high MELD scores (n = 1), comorbid conditions (n = 1), or technical considerations (n = 3). Of 20 patients who underwent embolization, 13 had persistent and 7 had recurrent HE; 100% (20/20) achieved immediate improvement. Durable benefit was achieved in 100% (18/18) and 92% (11/12) at 1‐4 and 6‐12 months, respectively. The majority (67%; 8/12) were free from HE‐related hospitalizations over 1 year; 10% developed procedural complications, and all resolved. Six developed new or worsening ascites. In conclusion, PSS embolization is a safe and effective treatment strategy that should be considered for select patients with medically refractory HE. Liver Transplantation 22 723–731 2016 AASLD.
A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia
Dakhil, Shaker R. , Novotny, Paul J. , Sloan, Jeff A. , Johnson, David B. , Anderson, Daniel M. , Mattar, Bassam, Moore, Dennis F., Nikcevich, Daniel A., Loprinzi, Charles L. , Steensma, David P.

Mayo Clinic

American Journal of Hematology | July 6, 2015 | Volume: 90 | Issue: 10 | Pages: 877-881

10.1002/ajh.24110 | PMID 26149465 Get It

Erythropoiesis‐stimulating agents (ESAs) epoetin alfa (EA) and darbepoetin alfa (DA) increase hemoglobin (Hb) levels and reduce red blood cell (RBC) transfusion requirements in patients with cancer chemotherapy‐associated anemia (CAA). Extended‐interval ESA dosing (administration less than once weekly) is common with DA, but previous studies suggested that EA might also be administered less often than weekly. In this multicenter prospective trial, 239 CAA patients with Hb <10.5 g/dL were randomized to receive EA 40,000 U subcutaneously once weekly (“40K” arm), EA 80,000 U every 3 weeks (“80K”), EA 120,000 U every 3 weeks (“120K” arm), or DA 500 mcg every 3 weeks (“DA”), for 15 weeks. The primary endpoint was the proportion of patients achieving Hb ≥ 11.5 g/dL or increment of Hb > 2.0 g/dL from baseline without transfusion. Secondary endpoints included transfusion requirements, adverse events (AEs), and patient‐reported outcomes (PROs). There were no significant differences between treatment arms in the proportion of patients achieving Hb response (68.9% for 40K, 61.7% for 80K, 65.5% for 120K, and 66.7% for DA; P > 0.41 for all comparisons) or requiring RBC transfusion, but the median Hb increment from baseline was higher in the 40K and DA arms compared to the two extended dosing EA arms, and Hb response was achieved soonest in the weekly EA arm. There were no differences in PROs or AEs. The FDA‐approved schedules tested—weekly EA 40,000 U, and every 3 week DA 500 mcg—are reasonable standards for CAA therapy. Am. J. Hematol. 90:877–881, 2015. © 2015 Wiley Periodicals, Inc.
Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis
Johnson, David H. , Khanna, Sahil , Smyrk, Thomas C. , Loftus, Edward V. , Anderson, Kari, Ahlquist, David A. , Mahoney, Douglas W. , Kisiel, John B. , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 30, 2014 | Volume: 39 | Issue: 12 | Pages: 1408-1417

10.1111/apt.12774 | PMID 24779703 Get It

SummaryBackgroundChronic ulcerative colitis (CUC) and colonic Crohn's disease (CD) increase colorectal neoplasia (CRN) risk. While sessile serrated polyp (SSP) is a known cancer precursor, serrated epithelial changes (SEC) are of uncertain prevalence and neoplastic risk.AimTo assess the serrated lesion detection rates in CUC and CD and documented incidence of subsequent CRN in a retrospective, single‐centre cohort study.MethodsPatients were identified by a central diagnostic index and pathology review confirmed SEC, SSP, CUC and CD diagnoses from 2006–12. Matched controls were identified from among all CUC and CD patients having colonoscopy during the second half of the time period. All were followed for incident CRN, estimated by the Kaplan–Meier method.ResultsBetween 2006 and 2012, 79 SEC and 10 SSP cases were identified. Detection rates were estimated to be 10/1000 and 2/1000 patients, for SEC and SSP respectively, among 4208 unique CUC or CD patients having colonoscopy from 2010–12. With only 10 cases, SSP patients were not further analysed. Cumulative incidence of subsequent CRN at 1 and 3 years was 12% (95% CI, 0–30%) and 30% (3–57%), respectively, in SEC patients compared to 4% (0–12%) and 9% (0–23%), respectively, in CUC or CD controls (P = 0.047, log‐rank). However, this statistical difference was not significant after patients were stratified for history of prior or synchronous dysplasia (P = 0.09).ConclusionsSerrated epithelial changes and sessile serrated polyps are uncommonly detected by colonoscopy in chronic ulcerative colitis and Crohn's disease patients. Histology with changes of serrated epithelium may be associated with risk of subsequent colorectal neoplasia, however further studies are needed to explore this relationship.
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Goss, Paul E., Budd, G. Thomas , Rabaglio, Manuela , Ansari, Rafat , Johnson, David B. , Tozer, Richard , D’Souza, David , Chalchal, Haji , Spadafora, Silvana , Stearns, Vered , Perez, Edith A. , Liedke, Pedro Emanuel Rubini , Láng, István, Elliott, Catherine, Chapman, Judy-Anne W., Shepherd, Lois E. , Ingle, James N. , Pritchard, Kathleen I. , Ellis, Matthew J. , Sledge, George W. , Gelmon, Karen A. , Chapman, Judy‐Anne W., Stearns, Vered , Rabaglio-Poretti, Manuela

Mayo Clinic

Journal of Clinical Oncology | January 28, 2013 | Volume: 31 | Issue: 11 | Pages: 1398-1404

10.1200/jco.2012.44.7805 | PMID 23358971 Get It

Purpose In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non–cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss. Patients and Methods We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease–free survival, incidence of contralateral new primary breast cancer, and safety. Results In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease–free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms. Conclusion This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor–positive breast cancer.
Robotic Intracorporeal Urinary Diversion: Ileal Conduit
Johnson, David C. , Castle, Erik P., Pruthi, Raj S. , Woods, Michael E.

Mayo Clinic

Journal of Endourology | October 26, 2012 | Volume: 26 | Issue: 12 | Pages: 1566-1569

10.1089/end.2012.0447 | PMID 23102129 Get It

Cool, warm, and heat‐pain detection thresholds
Dyck, Peter James , Zimmerman, I. R., Gillen, D. A., Johnson, David M. , Karnes, Jeannine L., O’Brien, Peter C.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 43 | Issue: 8 | Pages: 1500-1500

10.1212/wnl.43.8.1500 | PMID 8351002 Get It